- Home
- RCKT vs MCI Comparison
RCKT vs MCI Comparison
Compare RCKT & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCKT | MCI |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.2M | 410.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCKT | MCI |
|---|---|---|
| Price | $4.70 | $19.27 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $29.65 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 19.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.82 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $97.68 | N/A |
| P/E Ratio | ★ N/A | $10.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.19 | $18.00 |
| 52 Week High | $8.80 | $23.79 |
Technical Indicators
Market Signals| Indicator | RCKT | MCI |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 31.54 |
| Support Level | $2.99 | $19.05 |
| Resistance Level | $5.34 | $21.19 |
| Average True Range (ATR) | 0.38 | 0.40 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 47.90 | 4.66 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.